• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

使用鞘内化疗、放疗和达雷妥尤单抗治疗复发性中枢神经系统浆细胞瘤的持久治疗反应

Durable treatment response of relapsing CNS plasmacytoma using intrathecal chemotherapy, radiotherapy, and Daratumumab.

作者信息

Elhassadi Ezzat, Murphy Maurice, Hacking Dayle, Farrell Michael

机构信息

Department of Haematology University Hospital Waterford Waterford Ireland.

Department of Pathology University Hospital Waterford Waterford Ireland.

出版信息

Clin Case Rep. 2018 Mar 2;6(4):723-728. doi: 10.1002/ccr3.1451. eCollection 2018 Apr.

DOI:10.1002/ccr3.1451
PMID:29636948
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5889271/
Abstract

CNS myelomatous involvement is a rare complication of multiple myeloma with dismal outcome. This disease's optimal treatment is unclear. Combined approach of systemic therapy, radiotherapy, and intrathecal injections chemotherapy should be considered and autologous stem cell transplant consolidation is offered to eligible patients. The role of Daratumumab in this disease deserves further evaluation.

摘要

中枢神经系统骨髓瘤累及是多发性骨髓瘤的一种罕见并发症，预后不佳。该病的最佳治疗方法尚不清楚。应考虑采用全身治疗、放疗和鞘内注射化疗的联合方法，并为符合条件的患者提供自体干细胞移植巩固治疗。达雷妥尤单抗在这种疾病中的作用值得进一步评估。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/213c/5889271/11473af6b9f5/CCR3-6-723-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/213c/5889271/e8fafb9e0f2e/CCR3-6-723-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/213c/5889271/88825767939d/CCR3-6-723-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/213c/5889271/32076393f37c/CCR3-6-723-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/213c/5889271/13b1033e3c25/CCR3-6-723-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/213c/5889271/2d5b10e28d1d/CCR3-6-723-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/213c/5889271/6bfafcfa8b05/CCR3-6-723-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/213c/5889271/11473af6b9f5/CCR3-6-723-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/213c/5889271/e8fafb9e0f2e/CCR3-6-723-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/213c/5889271/88825767939d/CCR3-6-723-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/213c/5889271/32076393f37c/CCR3-6-723-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/213c/5889271/13b1033e3c25/CCR3-6-723-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/213c/5889271/2d5b10e28d1d/CCR3-6-723-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/213c/5889271/6bfafcfa8b05/CCR3-6-723-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/213c/5889271/11473af6b9f5/CCR3-6-723-g007.jpg

相似文献

1
Durable treatment response of relapsing CNS plasmacytoma using intrathecal chemotherapy, radiotherapy, and Daratumumab.使用鞘内化疗、放疗和达雷妥尤单抗治疗复发性中枢神经系统浆细胞瘤的持久治疗反应
Clin Case Rep. 2018 Mar 2;6(4):723-728. doi: 10.1002/ccr3.1451. eCollection 2018 Apr.
2
[Successful treatment of myelomatous pleural effusion with daratumumab administration before autologous peripheral stem cell transplantation].[在自体外周血干细胞移植前给予达雷妥尤单抗成功治疗骨髓瘤性胸腔积液]
Rinsho Ketsueki. 2020;61(8):879-884. doi: 10.11406/rinketsu.61.879.
3
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.在新诊断的多发性骨髓瘤患者中，硼替佐米、沙利度胺和地塞米松联合或不联合达雷妥尤单抗和自体干细胞移植治疗后，用达雷妥尤单抗或观察进行维持治疗（CASSIOPEIA）：一项开放标签、随机、3 期试验。
Lancet Oncol. 2021 Oct;22(10):1378-1390. doi: 10.1016/S1470-2045(21)00428-9. Epub 2021 Sep 13.
4
Successful treatment with pomalidomide and intrathecal injections for central nervous system plasmacytoma in a patient under haemodialysis.血液透析患者伴中枢神经系统浆细胞瘤采用泊马度胺和鞘内注射成功治疗。
J Clin Pharm Ther. 2020 Feb;45(1):221-225. doi: 10.1111/jcpt.13054. Epub 2019 Oct 10.
5
Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents.多发性骨髓瘤累及中枢神经系统：通过放疗、鞘内化疗和免疫调节剂可实现长期生存。
Br J Haematol. 2013 Aug;162(4):483-8. doi: 10.1111/bjh.12414. Epub 2013 Jun 15.
6
Secondary CNS myeloma with remission after systemic CNS-penetrating agents.经全身可穿透中枢神经系统的药物治疗后缓解的继发性中枢神经系统骨髓瘤。
Neurooncol Adv. 2022 Jul 1;4(1):vdac106. doi: 10.1093/noajnl/vdac106. eCollection 2022 Jan-Dec.
7
EMA Review of Daratumumab (Darzalex) for the Treatment of Adult Patients Newly Diagnosed with Multiple Myeloma.EMA 审查达雷妥尤单抗（Darzalex）治疗新诊断为多发性骨髓瘤的成年患者。
Oncologist. 2020 Dec;25(12):1067-1074. doi: 10.1002/onco.13554. Epub 2020 Oct 16.
8
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.自体造血干细胞移植对比硼替佐米-美法仑-泼尼松（联合或不联合硼替佐米-来那度胺-地塞米松巩固治疗）以及来那度胺维持治疗用于新诊断的多发性骨髓瘤（EMN02/HO95）：一项多中心、随机、开放标签的3期研究
Lancet Haematol. 2020 Jun;7(6):e456-e468. doi: 10.1016/S2352-3026(20)30099-5. Epub 2020 Apr 30.
9
Thiotepa intrathecal injections for myelomatous central nervous system involvement.噻替哌鞘内注射用于治疗骨髓瘤中枢神经系统受累。
Br J Haematol. 2021 Apr;193(2):e9-e12. doi: 10.1111/bjh.17343. Epub 2021 Mar 9.
10
A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome.巴尔干骨髓瘤研究组和巴塞罗那大学的一项真实世界多中心回顾性研究：分析改善预后的参数。
Haematologica. 2020 Jan;105(1):201-208. doi: 10.3324/haematol.2019.219295. Epub 2019 Jul 5.

引用本文的文献

1
Isolated relapse of multiple myeloma in the central nervous system post autologous hematopoietic stem cell transplantation: a case report and literature review.自体造血干细胞移植后中枢神经系统孤立性多发性骨髓瘤复发：一例报告及文献复习
Front Oncol. 2025 Jul 8;15:1628297. doi: 10.3389/fonc.2025.1628297. eCollection 2025.
2
Isolated central nervous system (CNS) relapse of multiple myeloma 11 years after autologous stem cell transplantation: a case report.自体干细胞移植11年后多发性骨髓瘤孤立性中枢神经系统复发：一例报告
AME Case Rep. 2024 Sep 12;8:111. doi: 10.21037/acr-24-19. eCollection 2024.
3
Combined daratumumab-pomalidomide and ultra-fractionated whole breast irradiation is safe!

本文引用的文献

1
Cancer Statistics, 2017.《2017 年癌症统计》
CA Cancer J Clin. 2017 Jan;67(1):7-30. doi: 10.3322/caac.21387. Epub 2017 Jan 5.
2
Myelomatous Involvement of the Central Nervous System.中枢神经系统的骨髓瘤累及
Clin Lymphoma Myeloma Leuk. 2016 Nov;16(11):644-654. doi: 10.1016/j.clml.2016.08.010. Epub 2016 Aug 10.
3
Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity.复发/难治性多发性骨髓瘤治疗模式的演变：选择增加，复杂性也增加。
达雷妥尤单抗-泊马度胺联合超分割全乳照射是安全的！
Rep Pract Oncol Radiother. 2024 Jul 22;29(3):409-411. doi: 10.5603/rpor.100780. eCollection 2024.
4
Case reports: Central nervous system involvement in patients with newly diagnosed multiple myeloma.病例报告：新诊断多发性骨髓瘤患者的中枢神经系统受累情况
Front Neurol. 2023 Feb 2;14:1072490. doi: 10.3389/fneur.2023.1072490. eCollection 2023.
5
Multiple myeloma with isolated central nervous system relapse after autologous stem cell transplantation: A case report and review of the literature.自体干细胞移植后孤立性中枢神经系统复发的多发性骨髓瘤：一例报告并文献复习
Front Oncol. 2022 Nov 25;12:1027585. doi: 10.3389/fonc.2022.1027585. eCollection 2022.
6
Secondary CNS myeloma with remission after systemic CNS-penetrating agents.经全身可穿透中枢神经系统的药物治疗后缓解的继发性中枢神经系统骨髓瘤。
Neurooncol Adv. 2022 Jul 1;4(1):vdac106. doi: 10.1093/noajnl/vdac106. eCollection 2022 Jan-Dec.
7
Central Nervous System Myeloma and Unusual Extramedullary Localizations: Real Life Practical Guidance.中枢神经系统骨髓瘤及不常见的髓外定位：现实生活中的实用指南
Front Oncol. 2022 Jul 7;12:934240. doi: 10.3389/fonc.2022.934240. eCollection 2022.
8
Advances in the treatment of extramedullary disease in multiple myeloma.多发性骨髓瘤髓外疾病的治疗进展
Transl Oncol. 2022 Aug;22:101465. doi: 10.1016/j.tranon.2022.101465. Epub 2022 Jun 6.
9
IgD multiple myeloma with central nervous system involvement: A case report and literature review.IgD型多发性骨髓瘤合并中枢神经系统受累：一例报告及文献复习
Mol Clin Oncol. 2021 Oct;15(4):198. doi: 10.3892/mco.2021.2360. Epub 2021 Aug 4.
10
Multiple Myeloma with Central Nervous System Relapse Early after Autologous Stem Cell Transplantation: A Case Report and Literature Review.自体造血干细胞移植后早期中枢神经系统复发的多发性骨髓瘤：病例报告及文献复习。
Intern Med. 2021;60(3):463-468. doi: 10.2169/internalmedicine.5646-20. Epub 2021 Feb 1.
Bone Marrow Transplant. 2016 Apr;51(4):479-91. doi: 10.1038/bmt.2015.307. Epub 2016 Jan 4.
4
How I treat extramedullary myeloma.我是如何治疗髓外骨髓瘤的。
Blood. 2016 Feb 25;127(8):971-6. doi: 10.1182/blood-2015-07-635383. Epub 2015 Dec 17.
5
Lack of survival improvement with novel anti-myeloma agents for patients with multiple myeloma and central nervous system involvement: the Greek Myeloma Study Group experience.新型抗骨髓瘤药物对合并中枢神经系统受累的多发性骨髓瘤患者生存率改善情况欠佳：希腊骨髓瘤研究组的经验
Ann Hematol. 2015 Dec;94(12):2033-42. doi: 10.1007/s00277-015-2484-y. Epub 2015 Sep 30.
6
Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations.新型药物时代的髓外骨髓瘤发展：来那度胺-硼替佐米联合用药并未增加风险的证据。
Br J Haematol. 2015 Jun;169(6):843-50. doi: 10.1111/bjh.13382.
7
Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse.软组织髓外多发性骨髓瘤的预后明显比骨相关髓外复发差。
Haematologica. 2014 Feb;99(2):360-4. doi: 10.3324/haematol.2013.094409. Epub 2013 Sep 13.
8
Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents.多发性骨髓瘤累及中枢神经系统：通过放疗、鞘内化疗和免疫调节剂可实现长期生存。
Br J Haematol. 2013 Aug;162(4):483-8. doi: 10.1111/bjh.12414. Epub 2013 Jun 15.
9
Central nervous system multiple myeloma--potential roles for intrathecal therapy and measurement of cerebrospinal fluid light chains.中枢神经系统多发性骨髓瘤——鞘内治疗和脑脊液轻链测量的潜在作用。
Br J Haematol. 2013 Aug;162(3):371-5. doi: 10.1111/bjh.12404. Epub 2013 May 29.
10
Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents.髓外疾病预示着多发性骨髓瘤的预后不良，即使在新型药物时代，高风险疾病中也存在过度表达。
Haematologica. 2012 Nov;97(11):1761-7. doi: 10.3324/haematol.2012.065698. Epub 2012 Jun 11.